Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D D Ho

Showing results (181-190 of 221) with videos related to

Pageof 23
Sort By:
The New England Journal of Medicine|May 26, 1999
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapyL Zhang, B Ramratnam, K Tenner-Racz, et al.
Science (New York, N.Y.)|April 26, 1996
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infectionS M Wolinsky, B T Korber, A U Neumann, et al.
The Journal of Biological Chemistry|April 25, 1987
Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelopeR C Kennedy, G R Dreesman, T C Chanh, et al.
The Journal of Experimental Medicine|November 7, 2001
Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapyH Mohri, A S Perelson, K Tung, et al.
The Journal of Infectious Diseases|June 2, 1998
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infectionM Markowitz, M Conant, A Hurley, et al.
Journal of Virology|May 1, 1997
Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeysZ Chen, A Luckay, D L Sodora, et al.
Journal of Virology|September 1, 1989
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120N C Sun, D D Ho, C R Sun, et al.
Molecular Medicine (Cambridge, Mass.)|November 9, 2000
An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytesX Jin, G Ogg, S Bonhoeffer, et al.
Journal of Virology|October 10, 1998
Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1L Zhang, T He, Y Huang, et al.
Ophthalmology|May 1, 1993
Endophthalmitis caused by the coagulase-negative staphylococci. 1. Disease spectrum and outcomeL D Ormerod, D D Ho, L E Becker, et al.
Pageof 23

Showing results (181-190 of 221) with videos related to

Sort By:
Pageof 23
The New England Journal of Medicine|May 26, 1999
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapyL Zhang, B Ramratnam, K Tenner-Racz, et al.
Science (New York, N.Y.)|April 26, 1996
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infectionS M Wolinsky, B T Korber, A U Neumann, et al.
The Journal of Biological Chemistry|April 25, 1987
Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelopeR C Kennedy, G R Dreesman, T C Chanh, et al.
The Journal of Experimental Medicine|November 7, 2001
Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapyH Mohri, A S Perelson, K Tung, et al.
The Journal of Infectious Diseases|June 2, 1998
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infectionM Markowitz, M Conant, A Hurley, et al.
Journal of Virology|May 1, 1997
Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeysZ Chen, A Luckay, D L Sodora, et al.
Journal of Virology|September 1, 1989
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120N C Sun, D D Ho, C R Sun, et al.
Molecular Medicine (Cambridge, Mass.)|November 9, 2000
An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytesX Jin, G Ogg, S Bonhoeffer, et al.
Journal of Virology|October 10, 1998
Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1L Zhang, T He, Y Huang, et al.
Ophthalmology|May 1, 1993
Endophthalmitis caused by the coagulase-negative staphylococci. 1. Disease spectrum and outcomeL D Ormerod, D D Ho, L E Becker, et al.
Pageof 23